Compare ETON & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ETON | IMMP |
|---|---|---|
| Founded | 2017 | 1987 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 683.7M | 58.2M |
| IPO Year | 2018 | 2012 |
| Metric | ETON | IMMP |
|---|---|---|
| Price | $26.96 | $0.55 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 3 |
| Target Price | ★ $39.33 | $5.50 |
| AVG Volume (30 Days) | 465.8K | ★ 867.5K |
| Earning Date | 05-12-2026 | 04-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $79,950,000.00 | N/A |
| Revenue This Year | $40.90 | $417.85 |
| Revenue Next Year | $47.23 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 104.94 | N/A |
| 52 Week Low | $13.09 | $0.29 |
| 52 Week High | $27.19 | $3.53 |
| Indicator | ETON | IMMP |
|---|---|---|
| Relative Strength Index (RSI) | 72.35 | 36.54 |
| Support Level | $16.23 | N/A |
| Resistance Level | N/A | $1.75 |
| Average True Range (ATR) | 1.19 | 0.06 |
| MACD | 0.07 | 0.10 |
| Stochastic Oscillator | 94.39 | 36.05 |
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has eight commercial rare disease products, INCRELEX, ALKINDI SPRINKLE, KHINDIVITM, GALZIN, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous and Nitisinone. It also has five additional product candidates in late-stage development: ET-600, Amglidia, ET-700, ET-800 and ZENEO hydrocortisone autoinjector.
Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.